Announcements Trials
Browse Landscape

Phase

Phase 2 146Phase 1 81Phase 1/2 44Phase 3 38Phase NA 8Phase 2/3 8Phase 4 4Phase EARLY_PHASE1 2

Status

Completed 4Unknown 3Withdrawn 2Terminated 2Enrolling by invitation 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Pancreatic Neoplasms 2

Interventions

Magnetic Resonance Spectroscopy 7Cyclophosphamide 6pembrolizumab 5Radiosurgery 5Nivolumab 4Fluorouracil 4Carboplatin 4Blood Specimen Collection 4Biopsy 4X-Rays 3Vincristine 3Surveys and Questionnaires 3Proflavine 3Positron-Emission Tomography 3Metformin 3Cisplatin 3Bevacizumab 3fludarabine phosphate 2durvalumab 2atezolizumab 2Varenicline 2Topotecan 2Taxes 2Specimen Handling 2Rituximab 2Radiotherapy 2Positron Emission Tomography Computed Tomography 2Oxaliplatin 2Leucovorin 2Letrozole 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Terminated × Gemcitabine × Clear all
NCT03519308 2024-03-15

A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer

Abramson Cancer Center at Penn Medicine

Phase EARLY_PHASE1 Terminated
3 enrolled 13 charts
Gastrointestinal

Pancreatic Neoplasms

NCT01276613 2019-05-02

Tissue Pharmacokinetics of Intraoperative Gemcitabine in Resectable Adenocarcinoma of the Pancreas

M.D. Anderson Cancer Center

Phase EARLY_PHASE1 Terminated
18 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡